A new commentary authored by experts at Children's National in the latest edition of Science: Translational Medicine points to the need for better incentives to encourage companies to develop and test therapies for children.
"Pediatricians who treat children with serious and life-threatening diseases often find themselves face to face with the inadequacies of pediatric drug development,” write Edward Connor, MD, director of the Office of Innovation Development and Investigational Therapeutics at Children’s National Medical Center, and Pablo Cure, MD, MPH, Laboratory for Entrepreneurial Achievement in Pediatrics (LEAP) Scholar in the Office of Innovation Development and Investigational Therapeutics.
In a previous commentary for this journal, Dr. Connor noted that despite the fact that children make up nearly 40 percent of the world’s population, little research is done to test the effects of “adult therapies” on children, who have unique needs requiring tailored care more sophisticated than merely smaller doses of adult therapeutics.
Developing better therapies specifically for children, whether drugs, devices, or techniques, is a key focus of the Sheikh Zayed Institute for Pediatric Surgical Innovation as well as many other research efforts at Children's National. Look for much more information about our efforts and important initiatives elsewhere in the near future. For more information about this commentary, read the media release.